Emerging World Pharma, Inc.
Emerging World Pharma, Inc.
Your view on EWPI
Overview
What the company does, where it operates, and who runs it.
About Emerging World Pharma, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Terry Agrivos
- Headquarters
- Pastoral Road, Sunyani, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Terry Agrivos
- Headquarters
- Pastoral Road, Sunyani, US
Emerging World Pharma, Inc. invests in generic based pharmaceutical companies manufacturing within developing nations. It provides production infrastructure, hiring and training of local employees, and raw materials to these companies.
The company focuses its investments on pharmaceutical companies that have contracts with church and other non government organizations, government, and wholesalers. Emerging World Pharma, Inc. was formerly known as Tubearoo, Inc. and changed its name to Emerging World Pharma, Inc. in November 2009.
The company was founded in 1997 and is based in Sunyani, Ghana.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Emerging World Pharma, Inc., and the rating behind it. EWPI last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Emerging World Pharma, Inc.. Starting points for Emerging World Pharma, Inc.: beta 162.64 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Emerging World Pharma, Inc.. Emerging World Pharma, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Emerging World Pharma, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Emerging World Pharma, Inc.. Emerging World Pharma, Inc. has reported as a listed company since 2000. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Emerging World Pharma, Inc. valued side by side against its closest peers. Emerging World Pharma, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Emerging World Pharma, Inc., and how their positions are changing. At a $11,930 market value, institutional positions materially move Emerging World Pharma, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Emerging World Pharma, Inc. executives and directors. Shares of Emerging World Pharma, Inc. have traded between $0.0000 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Emerging World Pharma, Inc.. Emerging World Pharma, Inc. is a $11,930 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Emerging World Pharma, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Emerging World Pharma, Inc.. Coverage tracks Emerging World Pharma, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.